This open-label, multi-center study is open to patients 1 to 18 years of age at time of
enrollment with medication resistant epilepsy.
Drug: Cannabidiol (Epidiolex)
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02397863
Ages eligible for Study
1 Years to 18 Years
Genders eligible for Study
Accepts Healthy Volunteers
Patient should have history of trying at least four antiepileptic drugs (AEDs), including one trial of a combination of two concomitant drugs, without successful seizure control. Vagal nerve stimulation, RNS deep brain stimulation, or the ketogenic diet can be considered equivalent to a drug trial.
Patient must be taking two or more AEDs at a dose which has been stable for at least four weeks.
A State of Georgia resident.
Patient is diagnosed as having Dravet Syndrome or Lennox-Gastaut Syndrome and eligible for a GW Pharmaceutical-Sponsored Clinical Trial.
Patients who have been part of a clinical trial involving another investigational product in the previous six months.
All locations for NCT02397863
United States (1)
Georgia Regents University
Augusta, Georgia, United States, 30912
View full eligibility
Tris trial is registered with FDA with number: NCT02397863. The sponsor of the trial is Augusta University and it is looking for 0 volunteers for the current phase.
Official trial title: An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!